The Spanish Association of Biosimilar Medicines (BIOSIM) welcomes the public consultation on the strategy of the joint network until 2025 and can only endorse the proposals to achieve the high-level objectives that are reflected in it. However, a comprehensive approach that maximizes the opportunities for greater access and lower cost that biosimilar medicines provide is missing throughout the paper.
